Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology
Details : Vivacitas' lead development candidate (AR-67) is a novel lipophilic next-generation camptothecin (Topiosomerase-1 enzyme inhibitor) compound with the potential to deliver improved efficacy and tolerability, employing a proprietary synthesis method.
Brand Name : AR-67
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 02, 2021
LOOKING FOR A SUPPLIER?
Reset All
